Video
Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer
Author(s):
Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Overall response rate in this phase II trial was 16% with durable responses. Median overall survival was 7 months and a 1-year survival rate of 33%.
Additionally, patients who were HPV positive had a response rate higher than those who were HPV negative.
Related Videos
Related Content
